Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. (IPSC) is calling a virtual 2026 Special Meeting of Stockholders on January 22, 2026 to vote on two key proposals. The first would amend its certificate of incorporation to allow the board, any time before June 30, 2026, to implement a reverse stock split of the company’s common stock at a ratio between 1‑for‑5 and 1‑for‑30, at the board’s discretion. A reverse split would reduce the number of shares outstanding but keep authorized shares the same, materially increasing authorized but unissued shares and proportionally adjusting outstanding options, RSUs, warrants and plan reserves.
The board states the main goal is to help IPSC regain and maintain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a deficiency notice and transfer to the Nasdaq Capital Market, and to broaden potential investor interest. The filing explains risks, including possible reduced liquidity, more odd-lot holdings, no guarantee of a sustained higher share price, and an increased pool of authorized but unissued shares that could affect future capital raising and control dynamics. The second proposal would permit adjournment of the meeting if more time is needed to secure enough votes or a quorum.
Century Therapeutics, Inc. (IPSC) President and CEO insider purchase was reported on a Form 4. The reporting person, who is also a director, bought 35,000 shares of Century Therapeutics common stock on 11/19/2025 at a weighted average price of $0.4951 per share. Following this open-market purchase, the insider beneficially owns 3,271,453 shares, held directly. The filing notes that all profits from the reported transactions will be disgorged to the issuer pursuant to applicable requirements, and the price reflects multiple trades between $0.488 and $0.5005 per share.
Century Therapeutics, Inc. (IPSC) reported an insider transaction by its President and CEO, who is also a director of the company. On 11/17/2025, the reporting person sold 32,456 shares of common stock at a price of $0.454 per share.
According to the explanation provided, these sales represent shares sold to cover tax withholding obligations arising from the vesting of restricted stock units and were described as automatic, not at the discretion of the reporting person. After this transaction, the reporting person beneficially owned 3,236,453 shares of Century Therapeutics common stock, held directly.
Century Therapeutics, Inc. (IPSC) furnished materials related to its latest quarter and pipeline. The company provided an earnings press release for the quarter ended September 30, 2025, and an updated investor presentation. It also announced its first Type 1 diabetes program, CNTY-813.
The earnings release (Exhibit 99.1), investor presentation (Exhibit 99.2), and CNTY-813 press release (Exhibit 99.3) were furnished on November 13, 2025 and are not deemed “filed” under the Exchange Act.
Century Therapeutics (IPSC) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $34,422 as collaboration revenue fell to zero following the Bristol‑Myers Squibb termination. For the nine months, the company posted net income of $9,591, driven by $109,164 of collaboration revenue recognized in Q1 when option rights expired.
Total assets were $244,717 versus $353,216 at year‑end, reflecting lower investments and lease assets. Cash, cash equivalents and investments were $132,748 as of September 30, 2025. Current liabilities declined to $22,026 from $129,782, primarily as deferred revenue was recognized. Stockholders’ equity rose to $176,348.
Q3 operating expenses were $36,124, including R&D $22,526, G&A $6,835, and a $6,763 impairment tied to lease strategy changes. The company executed lease modifications, recording a $1,395 gain and expects Seattle and Boston lease terminations by early 2026 with a new Watertown lease to commence thereafter. Management states it has adequate resources to operate for at least the next 12 months. As of November 1, 2025, common shares outstanding were 87,307,091.
Century Therapeutics (IPSC) insider transaction: The company’s SVP Finance & Operations reported selling 292 shares of common stock at $0.586 on November 3, 2025.
The filing states these sales were executed to satisfy tax withholding obligations tied to the vesting of restricted stock units and were automatic, not at the reporting person’s discretion. Following the transaction, the insider beneficially owns 405,131 shares, held directly.
Century Therapeutics insider filing reports a grant of restricted stock units to the company’s Chief Scientific Officer. The report shows 762,543 RSUs were granted on 09/18/2025; each RSU represents a contingent right to one share of common stock and will be settled in shares on each vesting date. The RSUs vest 50% on October 1, 2026 and the remaining 50% on October 1, 2027, subject to continued service. After the grant the reporting person beneficially owns 992,489 shares directly and 10,697 shares indirectly via the Cowan Investment Nominee Trust, which the filer disclaims except for any pecuniary interest.
Douglas Carr, SVP Finance & Operations reported a small, automated sale of company stock to cover tax withholding related to restricted stock unit vesting. On 09/08/2025 he disposed of 263 shares of Century Therapeutics, Inc. (IPSC) at $0.50 per share, leaving 405,423 shares beneficially owned in a direct capacity.
The Form 4 states the sales were automatic and not at the reporting person’s discretion, made solely to satisfy tax-withholding obligations. The filing is signed by the reporting person on 09/10/2025.
Brent Pfeiffenberger, President and CEO and Director of Century Therapeutics, Inc. (IPSC), reported a small automatic sale of common stock on 09/08/2025 to satisfy tax withholding related to the vesting of restricted stock units. The Form 4 shows 488 shares were sold at $0.50 per share, and following the reported transaction the reporting person beneficially owns 3,268,909 shares, held directly. The filing states the sales were automatic to cover tax obligations and not at the reporting person’s discretion.
Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, Inc. (IPSC), reported transactions on Form 4 showing an automatic sale of 539 shares of common stock on 09/08/2025 at a price of $0.50 per share to satisfy tax withholding related to the vesting of restricted stock units. After the reported sale, Mr. Russotti is shown as directly owning 391,508 shares and indirectly owning 92,773 shares through the Gregory Russotti 2021 Family Trust. The filing was signed by an attorney-in-fact on 09/10/2025. The Form 4 notes the sales were automatic and not made at the reporting person's discretion.